Trial · NCT01772472
Outcomes29
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 29
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Invasive Disease-free Survival (IDFS) Rate at 3 Years | At Year 3 | ITT population included all participants who were randomized to the study regardless of whether they received any study treatment. | percentage of participants | NUMBER |
| OTHER_PRE_SPECIFIED | IDFS Rate at 7 Years | At Year 7 | ITT population included all participants who were randomized to the study regardless of whether they received any study treatment. | percentage of participants | NUMBER |
| OTHER_PRE_SPECIFIED | IDFS Rate at 8 Years | At Year 8 | ITT population included all participants who were randomized to the study regardless of whether they received any study treatment. | percentage of participants | NUMBER |
| SECONDARY | IDFS Including Second Primary Non-breast Cancer (SPNBC) Rate at 3 Years | At Year 3 | ITT population included all participants who were randomized to the study regardless of whether they received any study treatment. | percentage of participants | NUMBER |
| SECONDARY | IDFS Including SPNBC Rate at 7 Years | At Year 7 | ITT population included all participants who were randomized to the study regardless of whether they received any study treatment. | percentage of participants | NUMBER |
| SECONDARY | IDFS Including SPNBC Rate at 8 Years | At Year 8 | ITT population included all participants who were randomized to the study regardless of whether they received any study treatment. | percentage of participants | NUMBER |
| SECONDARY | Disease-free Survival (DFS) Rate at 3 Years | At Year 3 | ITT population included all participants who were randomized to the study regardless of whether they received any study treatment. | percentage of participants | NUMBER |
| SECONDARY | DFS Rate at 7 Years | At Year 7 | ITT population included all participants who were randomized to the study regardless of whether they received any study treatment. | percentage of participants | NUMBER |
| SECONDARY | DFS Rate at 8 Years | At Year 8 | ITT population included all participants who were randomized to the study regardless of whether they received any study treatment. | percentage of participants | NUMBER |
| SECONDARY | Overall Survival (OS) Rate at 5 Years | At Year 5 | ITT population included all participants who were randomized to the study regardless of whether they received any study treatment. | percentage of participants | NUMBER |
| SECONDARY | OS Rate at 7 Years | At Year 7 | ITT population included all participants who were randomized to the study regardless of whether they received any study treatment. | percentage of participants | NUMBER |
| SECONDARY | OS Rate at 8 Years | At Year 8 | ITT population included all participants who were randomized to the study regardless of whether they received any study treatment. | percentage of participants | NUMBER |
| SECONDARY | Distant Recurrence-free Interval (DRFI) Rate at 3 Years | At Year 3 | ITT population included all participants who were randomized to the study regardless of whether they received any study treatment. | percentage of participants | NUMBER |
| SECONDARY | DRFI Rate at 7 Years | At Year 7 | ITT population included all participants who were randomized to the study regardless of whether they received any study treatment. | percentage of participants | NUMBER |
| SECONDARY | DRFI Rate at 8 Years | At Year 8 | ITT population included all participants who were randomized to the study regardless of whether they received any study treatment. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | From signing of informed consent till end of follow up (up to approximately 131 months) | SE population included all randomized participants who received any amount of study treatment. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Cardiac Events as Adjudicated by the Cardiac Review Committee | Up to approximately 126 months | SE population included all randomized participants who received any amount of study treatment. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Hepatotoxicity Events as Adjudicated by the Hepatic Review Committee | Up to approximately 64 months | SE population included all randomized participants who received any amount of study treatment. | percentage of participants | NUMBER |
| SECONDARY | Number of Participants Who Discontinued Treatment Due to AEs | Up to approximately 9.6 months | SE population included all randomized participants who received any amount of study treatment. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With AEs and SAEs Leading to Death | From signing of informed consent till end of follow up (up to approximately 131 months) | SE population included all randomized participants who received any amount of study treatment. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01772472/outcomes